P575 Real-world effectiveness and safety of ustekinumab for the treatment of refractory Crohn’s disease: The Scottish ustekinumab cohort
ECCO'20 Vienna
2020
P576 The value of small bowel capsule endoscopy in the change of therapeutic management in patients with established Crohn’s disease
ECCO'20 Vienna
2020
P578 Inter-observer agreement of an expert panel for gastrointestinal ultrasound in ulcerative colitis
ECCO'20 Vienna
2020
P580 Irritable bowel syndrome in inflammatory bowel disease after remission: correlation with remission patterns and inflammation
ECCO'20 Vienna
2020
P581 Allogeneic expanded adipose-derived mesenchymal stem cell therapy for perianal fistulas in Crohn’s disease: First real-life experiences
ECCO'20 Vienna
2020
P584 Use of mycophenolate mofetil in inflammatory bowel disease: results from the ENEIDA registry
ECCO'20 Vienna
2020
P586 Higher infliximab and adalimumab trough levels are associated with fistula healing in patients with fistulising perianal Crohn’s disease
ECCO'20 Vienna
2020
P587 Adalimumab in pediatric Crohn’s disease: A long-term multi-centre real-world experience
ECCO'20 Vienna
2020
P588 vedolizumab trough levels at week 6 and 14 correlate with clinical remission in inflammatory bowel disease patients
ECCO'20 Vienna
2020
P589 Longer-term outcomes in patients with Crohn’s disease who are primary non-responders to anti-TNF in a single UK centre
ECCO'20 Vienna
2020
P590 Outcomes of patients treated with sequential anti-TNF therapy in a tertiary referral centre
ECCO'20 Vienna
2020
P591 Therapeutic management in inflammatory bowel disease: Differences in two IBD inception cohorts: 1991–93 and 2010–11 enrolled in the north-west of Spain
ECCO'20 Vienna
2020
P592 Frequency and causes of prolongation of the induction course of tofacitinib in patients with ulcerative colitis in conditions of real clinical practice
ECCO'20 Vienna
2020